A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data
Open Access
- 1 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 25 (8), 1533-1542
- https://doi.org/10.1007/s10147-020-01692-z
Abstract
Background In a phase III clinical trial, CheckMate 025, treatment of metastatic renal cell carcinoma (mRCC) with nivolumab demonstrated superior efficacy over everolimus. However, as the clinical trial excluded patients with specific complications and poor performance status (PS), the effectiveness and safety of nivolumab in clinical practice, in which patients with various clinical complications are treated, is unclear. This study explored real-world nivolumab treatment in Japanese mRCC patients. Methods This is an interim analysis of a multicenter, non-interventional, medical record review study (minimum follow-up: 9 months). All eligible Japanese mRCC patients who first received nivolumab between February and October 2017 were included; data cut-off was April 2019. We analyzed nivolumab treatment patterns, efficacy (including overall survival, progression-free survival, objective response rate, and duration of response) and safety (including immune-related adverse events). Results Of 208 evaluable patients, 31.7% received nivolumab as fourth- or later line of treatment. At data cut-off, 26.9% of patients were continuing nivolumab treatment. The major reason for discontinuation was disease progression (n = 100, 65.8%). Median overall survival was not reached; the 12-month survival rate was 75.6%. Median progression-free survival was 7.1 months, the objective response rate was 22.6%, and median duration of response was 13.3 months. Patients who were excluded or limited in number in CheckMate 025, such as those with non-clear cell RCC or poor PS, also received benefits from nivolumab treatment. Immune-related adverse events occurred in 27.4% of patients (grade >= 3, 10.1%). Conclusion Nivolumab was effective and well-tolerated in real-world Japanese mRCC patients.Funding Information
- Ono Pharmaceutical
- Bristol-Myers Squibb
This publication has 18 references indexed in Scilit:
- Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 studyJapanese Journal of Clinical Oncology, 2019
- Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future DirectionsEuropean Urology, 2018
- Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in JapanInternational Journal of Urology, 2018
- Immunonkologie beim Nierenzellkarzinom – Aktueller StandAktuelle Urologie, 2018
- Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 studyJapanese Journal of Clinical Oncology, 2017
- Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapyDrug Design, Development and Therapy, 2017
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaThe New England Journal of Medicine, 2015
- Urologic cancer in Japan: role of Japan at the frontier of issues in AsiaJapanese Journal of Clinical Oncology, 2015
- Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) projectJapanese Journal of Clinical Oncology, 2015
- Use of Targeted Therapies for Advanced Renal Cell Carcinoma in the Asia-Pacific Region: Opinion Statement From China, Japan, Taiwan, Korea, and AustraliaClinical Genitourinary Cancer, 2014